Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus DILACOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus DILACOR XR.
ADALAT CC vs DILACOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker